Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

APEL Appoints Senior Director

Published: Thursday, August 16, 2012
Last Updated: Thursday, August 16, 2012
Bookmark and Share
Appointment of Dr Susan Wood as Senior Director, Market Access.

Astellas Pharma Europe Ltd. (APEL) has appointed Dr Susan Wood as Senior Director, Market Access for Astellas Pharma Europe Ltd (APEL).

Formerly Senior Brand Director of APEL’s Pain Management franchise, she will now drive the Company’s market access activities with the aim of establishing its leadership in an area of ever increasing importance, in the face of current economic challenges.

She will report directly to Kay Drake, Vice President Marketing, Astellas Pharma Europe Ltd.

Welcoming Susan Wood to her new role, Ken Jones, President and CEO, Astellas Pharma Europe Ltd, said: “Astellas has proved time and again in recent years that it remains entirely possible to introduce effective new medicines that deliver value for payers - and that health services across Europe are willing to fund. Sue will be working closely with our Affiliates to drive the market access strategy across the Astellas Europe organization in our key therapeutic areas, focusing on developing evidence-based models from the early stages of R&D until the mature stages of the product lifecycle.”

Over the past three years, Susan Wood led the launch of QUTENZA™, an innovative treatment for peripheral neuropathic pain.

The successful introduction of QUTENZA has confirmed the value of integrating market access expertise at an early stage of strategic planning, and has also profiled Dr Wood’s abilities as a leader.

Commenting on her appointment, Susan Wood said: “Astellas Pharma Europe has recently launched its Oncology franchise, we are expecting some 11 products to be in launch or early-growth phase in the next three years. We are growing fast in Anti-Infectives, with the recently launched anti-infective DIFICLIR™, the first new treatment in 50 years for clostridium difficile (C.diff), and we continue to affirm our category leadership in Transplantation and Urology. I am very much looking forward to the challenge of supporting the company to achieve its strategic objectives.”

Susan Wood joined Astellas Pharma Europe Ltd in 2008 and has over 13 years’ experience in international pharmaceutical marketing, with a particular focus on launch strategies.

She previously held roles with Hoffmann-La Roche in Basel, Biogen in Paris and Sanofi Pasteur in Lyon. Before entering the pharmaceutical industry, she worked in clinical research.

Her academic background lies in neuroscience, with studies at both Oxford University and Harvard Medical School, and she has a PhD in Biochemistry, specializing in general anaesthesia.

Before entering the pharmaceutical industry she was also assistant editor of an international neuroscience journal.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,600+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
ASMS 2016: Targeting Mass Spectrometry Tools for the Masses
The expanding application range of MS in life sciences, food, energy, and health sciences research was highlighted at this year's ASMS meeting in San Antonio, Texas.
Long-Term Culturing of Adult Stem Cells
A new procedure developed by Harvard Stem Cell Institute researchers (HSCI) at Massachusetts General Hospital (MGH) may revolutionize the culturing of adult stem cells.
Solutions for Biotherapeutic Characterization
Innovation to speed the routine.
Plant-Based Vaccine Among Front Runners In Search For New Polio Jab
A researcher from Norwich is part of a consortium that has been awarded $1.5 million to develop safer polio vaccines, using a new technique developed at the John Innes Centre.
Harnessing Helpful Microbes
Seeking to further harness microbes’ many uses, the federal government has launched the National Microbiome Initiative (NMI) to “foster the integrated study of microbiomes across different ecosystems.”
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
A New Approach to Chemical Synthesis
Communesins, originally found in fungus, could hold potential as cancer drugs.
Better Animal Model to Improve HIV Vaccine Development
Penn study identifies a new tool to produce better HIV vaccine designs.
First Large-Scale Proteogenomic Study of Breast Cancer
The study offers understanding of potential therapeutic targets.
Developing a More Precise Seasonal Flu Vaccine
During the 2014-15 flu season, the poor match between the virus used to make the world’s vaccine stocks and the circulating seasonal virus yielded a vaccine that was less than 20 percent effective.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,600+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!